XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Statements of Cash Flows - USD ($)
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash Flows From Operating Activities    
Net Income (Loss) $ (11,955,226) $ (14,578,765)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 1,312,696 1,945,913
Depreciation of property and equipment 187,267 145,901
Amortization of debt discount 313,446 52,431
Non-cash rent expense 280,968  
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (1,514) (461,761)
License fee and expense reimbursements receivables 754,780 1,095,831
Deferred clinical supply costs (1,293,395) (1,538,380)
Security and equipment deposits 1,750 (68,868)
Accounts payable (115,534) 1,072,690
Accrued compensation (734,073) (529,534)
Accrued expenses and other current liabilities (139,645) (21,417)
Lease liabilities (284,996) 2,356
Net Cash Used In Operating Activities (11,673,476) (12,883,603)
Cash Flows From Investing Activities    
Purchases of property and equipment (2,122,197) (281,342)
Vendor deposits for property and equipment   (118,298)
Net Cash Used In Investing Activities (2,122,197) (399,640)
Cash Flows From Financing Activities    
Proceeds from sale of common stock and warrants in direct offering   14,981,299
Payment of offering issuance costs   (83,391)
Proceeds from sale of common stock in At the Market offering 4,023,414 886,974
Payment of issuance costs for At the Market offering (120,702) (26,609)
Proceeds from exercise of stock options 27,200 18,701
Proceeds from note payable to Avenue 5,000,000  
Payment of issuance costs for notes issued to Avenue (125,982)  
Repayments of notes payable (403,689) (448,999)
Net Cash Provided By Financing Activities 8,400,241 15,327,975
Net (Decrease) Increase in Cash and Cash Equivalents (5,395,432) 2,044,732
Cash, cash equivalents and restricted cash - Beginning of Period 22,863,520 27,336,850
Cash, cash equivalents and restricted cash - End of Period 17,468,088 29,381,582
Cash, cash equivalents and restricted cash consisted of the following:    
Cash and cash equivalents 17,468,088 21,506,582
Restricted cash   7,875,000
Total 17,468,088 29,381,582
Supplemental Disclosure of Cash Flow Information:    
Interest 699,116 199,367
Supplemental Disclosure of Non-Cash Investing and Financing Activities    
Purchase of insurance policy financed by note payable 609,140 675,331
Right-of-use assets and lease liabilities recognized upon lease renewal 904,437  
Vendor deposits applied to purchases of property and equipment 468,376  
Original issue discount on notes payable 212,500  
Cashless exercise of stock options 2  
Issuance of common stock related to vested restricted stock units $ 4 $ 7